Q2 EPS Estimates for Veeva Systems Increased by Analyst

Veeva Systems Inc. (NYSE:VEEV) – Stock analysts at Zacks Research boosted their Q2 2026 EPS estimates for shares of Veeva Systems in a report released on Wednesday, March 26th. Zacks Research analyst R. Department now anticipates that the technology company will post earnings of $1.22 per share for the quarter, up from their previous estimate of $1.14. The consensus estimate for Veeva Systems’ current full-year earnings is $4.35 per share. Zacks Research also issued estimates for Veeva Systems’ Q3 2026 earnings at $1.33 EPS, Q4 2026 earnings at $1.31 EPS, Q1 2027 earnings at $1.32 EPS and Q2 2027 earnings at $1.35 EPS.

Several other analysts have also commented on VEEV. Evercore ISI boosted their price target on Veeva Systems from $220.00 to $245.00 and gave the company an “in-line” rating in a research note on Friday, December 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $270.00 target price on shares of Veeva Systems in a report on Thursday, March 6th. Citigroup increased their target price on shares of Veeva Systems from $281.00 to $307.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. The Goldman Sachs Group lowered shares of Veeva Systems from a “buy” rating to a “sell” rating and reduced their price target for the company from $261.00 to $200.00 in a research report on Thursday, January 23rd. Finally, Stifel Nicolaus raised their price objective on shares of Veeva Systems from $240.00 to $272.00 and gave the stock a “buy” rating in a report on Friday, December 6th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $256.52.

Veeva Systems Trading Down 1.4 %

VEEV stock opened at $234.10 on Friday. Veeva Systems has a 1-year low of $170.25 and a 1-year high of $258.93. The business’s 50 day moving average is $231.62 and its 200-day moving average is $222.87. The firm has a market cap of $38.01 billion, a P/E ratio of 57.80, a P/E/G ratio of 1.89 and a beta of 0.88.

Hedge Funds Weigh In On Veeva Systems

Institutional investors have recently modified their holdings of the stock. MassMutual Private Wealth & Trust FSB boosted its stake in Veeva Systems by 72.5% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 119 shares of the technology company’s stock worth $25,000 after acquiring an additional 50 shares during the last quarter. Centricity Wealth Management LLC bought a new position in shares of Veeva Systems during the fourth quarter worth $25,000. Smithfield Trust Co grew its holdings in shares of Veeva Systems by 145.5% in the 4th quarter. Smithfield Trust Co now owns 135 shares of the technology company’s stock valued at $27,000 after buying an additional 80 shares during the period. True Wealth Design LLC raised its stake in Veeva Systems by 3,375.0% during the 3rd quarter. True Wealth Design LLC now owns 139 shares of the technology company’s stock worth $29,000 after buying an additional 135 shares during the period. Finally, Avion Wealth lifted its holdings in Veeva Systems by 635.0% during the fourth quarter. Avion Wealth now owns 147 shares of the technology company’s stock worth $30,000 after acquiring an additional 127 shares in the last quarter. 88.20% of the stock is currently owned by institutional investors and hedge funds.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.